drugset / Trial / NCT01430403

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

NCT01430403

RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this trial is to compare the efficacy of 4 to 5 months of three treatments - omalizumab, corticosteroid therapy boost, and placebo - in reducing fall exacerbations in inner-city children and adolescents with allergic persistent asthma when initiated approximately 4 -6 weeks prior to the start of the first day of each participant's school year.

Timeline

Start
2011-09
Primary completion
2013-12
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified 200 ug Inhaled
Subject Fluticasone Other / unclassified 500 ug Inhaled
Subject Omalizumab Monoclonal antibody 0.016 unknown Subcutaneous

Indications